The Technical Analyst
Kiniksa Pharmaceuticals [KNSA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kiniksa Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.73% $18.34
America/New_York / 24 apr 2024 @ 09:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 295.08 mill |
| EPS: | 0.200 |
| P/E: | 91.70 |
| Earnings Date: | Apr 23, 2024 |
| SharesOutstanding: | 70.62 mill |
| Avg Daily Volume: | 0.367 mill |
| RATING 2024-04-23 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 91.70 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 15.60x |
| Company: PE 91.70 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$34.80 (89.72%) $16.46 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 17.63 - 19.05 ( +/- 3.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Patel Sanj K | Buy | 129 750 | Share Option |
| 2024-04-08 | Patel Sanj K | Buy | 9 992 | Class A Common Share |
| 2024-04-08 | Patel Sanj K | Sell | 4 075 | Class A Common Share |
| 2024-04-04 | Patel Sanj K | Buy | 24 950 | Restricted Share Unit |
| 2024-04-08 | Patel Sanj K | Sell | 9 992 | Restricted Share Unit |
| INSIDER POWER |
|---|
| 24.60 |
| Last 100 transactions |
| Buy: 576 726 | Sell: 364 070 |
Forecast:
11:38 - $18.09
Live Trading Signals (every 1 min)
Forecast
1: 10:08 - $18.44
Forecast 2: 10:58 - $18.26
Forecast 3: 11:38 - $18.09
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $18.34 (3.73% ) |
| Volume | 0.0421 mill |
| Avg. Vol. | 0.367 mill |
| % of Avg. Vol | 11.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KNSA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $18.91 | N/A | Active |
|---|
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Latest Press Releases
2024-04-23 07:30:00 - Press Release
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results And Recent Portfolio Execution
– arcalyst ® (rilonacept) q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – arcalyst 2024 expected net product revenue increased to $370 - $390 million – – abiprubart phase 2b trial in sjÖgren's disease planned to initiate in 2h 2024 – – current operating plan expected to remain cash flow positive on an annual basis – – conference call and webcast scheduled for 8:30 am et today –
2024-04-16 16:01:00 - Press Release
Kiniksa Pharmaceuticals To Report First Quarter 2024 Financial Results On April 23, 2024
Hamilton, bermuda, april 16, 2024 (globe newswire) -- kiniksa pharmaceuticals, ltd. (nasdaq: knsa) announced today that it will host a conference call and live webcast on tuesday, april 23, 2024 at 8:30 a.m. eastern time to report its first quarter 2024 financial results and recent portfolio execution.
2024-04-02 07:30:00 - Press Release
Kiniksa Pharmaceuticals Announces Development Indication For Abiprubart
– abiprubart phase 2b trial in sjogren's disease planned to initiate in 2h 2024 – – abiprubart phase 2 cohort 4 rheumatoid arthritis data further validate biological activity – – abiprubart development in sjogren's disease fully funded through phase 3 – – company expects to remain cash flow positive on an annual basis within current operating plan –
2024-02-28 07:30:00 - Press Release
Kiniksa Pharmaceuticals Reports Fourth Quarter And Full-year 2023 Financial Results And Recent Portfolio Execution
– arcalyst ® (rilonacept) q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
2024-02-21 16:01:00 - Press Release
Kiniksa Pharmaceuticals To Report Fourth Quarter And Full-year 2023 Financial Results On February 28, 2024
Hamilton, bermuda, feb. 21, 2024 (globe newswire) -- kiniksa pharmaceuticals, ltd. (nasdaq: knsa) announced today that it will host a conference call and live webcast on wednesday, february 28, 2024 at 8:30 a.m. eastern time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.
Latest News
2024-04-23 09:41:06 - Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.14.
2024-04-16 16:01:00 - GlobeNewsWire
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution.
2024-03-01 10:56:12 - Zacks Investment Research
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-29 13:01:06 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?
2024-02-29 07:51:03 - Zacks Investment Research
New Strong Buy Stocks for February 29th
UGP, KNSA, EIG, AMSF and HMC have been added to the Zacks Rank #1 (Strong Buy) List on February 29, 2023.
2024-02-28 09:51:07 - Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
2024-02-28 09:40:27 - Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share.
2024-02-21 16:01:00 - GlobeNewsWire
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.
2024-02-12 10:56:04 - Zacks Investment Research
Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-12 09:51:11 - Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.